{
    "clinical_study": {
        "@rank": "43493", 
        "acronym": "Escitalopram", 
        "arm_group": [
            {
                "arm_group_label": "escitalopram", 
                "arm_group_type": "Experimental", 
                "description": "escitalopram 15mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo 15mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Purpose : to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in\n      Alzheimer's Disease\n\n      Trial Design : A 12-week, randomized, double-blind, parallel-group, placebo-controlled trial\n      with an open-label, 12-week extension"
        }, 
        "brief_title": "Escitalopram for the Treatment of Depression in Alzheimer's Disease", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "Clinical trial agreement signed by the parties to the subjects through a process of\n      screening. if it is consider suitable for evaluating through the selection / exclusion\n      criteria, they will be randomly assigned to the test group or control group (placebo).\n\n      Assigned to the test group or control subjects, they will be prescribe the 5mg Escitalopram\n      or Placebo. without regard to meals, it will be taking once a day.\n\n      and than It should be increased the capacity every two weeks by 5mg/day up to a maximum\n      15mg/day.\n\n      and than, on the treatment for a 8 weeks, If you don't find the side effect, Maintaining the\n      same capacity. If you find the side effect, you should lose capacity.(10mg/day)\n\n      The test group or control subjects,  will receive a doctor's examination and inspection\n      through six visits for a 24weeks from the date of the randomly assigned participants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1) over the age of 50\n\n        2) Medical diagnostic criteria must meet the standard.\n\n          1. Subject diagnosed with Alzheimer's disease in accordance with NINCDS-ADRDA Criteria.\n\n          2. Subject with three or more symptoms of the Olin depression (major depressive episode)\n             diagnostic criteria.\n\n          3. clinical dementia rating (CDR) of 0.5 to 2\n\n          4. MMSE 10 ~ 26 (K-MMSE)\n\n          5. GDS-15 \u2265 5 points\n\n        3) When screening, Cholinesterase inhibitors taking a minimum of four weeks or more stable\n        subject.\n\n        4) During the clinical trials, Subject does not change the capacity of Cholinesterase\n        Inhibitors.\n\n        5) MRI or CT results within 24 months of subject with Alzheimer's disease (AD)\n\n        6) Participation in clinical trials to determine their own and written informed consent\n        form and subject who actively perform clinical procedure including the questionnaire. But\n        the subjects with cognitive dysfunction that cannot voluntarily make the decision, can be\n        determined by an authorized representative to participate in.\n\n        7) Subjects must be accompanied their guardian to every visit. More than three days a\n        week, more than 4 hours per day, spend the day with the guardian.\n\n        Exclusion Criteria:\n\n          1. If you are taking other depression drugs within 4 weeks before the start of the\n             clinical trials(e.g. SSRI, Stablon, TCA, wellbutrin, ixel)\n\n          2. If you have any other mental illness (bipolar disorder, schizophrenia, etc.)\n\n          3. If you have a serious medical illness (heart failure, angina pectoris, myocardial\n             infarction, arteriosclerosis, etc.) or psychiatric illness.\n\n          4. Seizures, brain surgery, organic brain disease and history of organic affective\n             disorder and at the brain MRI, abnormalities other than brain atrophy.\n\n          5. If you have a history of the test drug hypersensitivity\n\n          6. If you are taking memantin (dementia)\n\n          7. If you participated in another clinical trial within 3 months.\n\n          8. If pregnant or fertile women, who have not received sterilization or if you do not\n             want to use an effective method of contraception.\n\n          9. In laboratory tests, if you have kidney failure or liver failure.\n\n         10. If you have history or habitual drinking or a history of drug abuse.\n\n         11. Uncontrolled diabetes or hypertension.\n\n         12. If determined to be inappropriate for clinical trials."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841125", 
            "org_study_id": "ADD_E_2010"
        }, 
        "intervention": [
            {
                "arm_group_label": "escitalopram", 
                "description": "escitalopram 15mg, QD(once a day), Oral medication, 24weeks", 
                "intervention_name": "escitalopram", 
                "intervention_type": "Drug", 
                "other_name": "lexacure Tab"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "placebo 15mg, QD(once a day), Oral medication", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexetimide", 
                "Citalopram"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alzheimer's Disease", 
            "depressive disorder"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Secho-gu banpo-dong", 
                    "zip": "505"
                }, 
                "name": "MedicalExcellence"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease", 
        "overall_official": [
            {
                "affiliation": "Kunkuk Universicy Hospital", 
                "last_name": "Seol-Heui HAN, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul St. Mary's Hospital", 
                "last_name": "Dong-Won YANG, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Sung-Yoon KIM, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Hospital", 
                "last_name": "Kun-Woo PARK, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hanlym University Hospital", 
                "last_name": "Do-Hoon KIM, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AJU University Hospital", 
                "last_name": "So-Young MUN, Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in CSDD(Cornell scale for depression in dementia) from baseline after 12 weeks of between treatment groups.", 
            "measure": "Change in CSDD(Cornell scale for depression in dementia) from baseline after 12 weeks of between treatment groups", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841125"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Konkuk University Medical Center", 
            "investigator_full_name": "Seol-Heui Han", 
            "investigator_title": "Clinical Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in CSDD(Cornell scale for depression in dementia) at week 4, 8, 16  and 24.", 
                "measure": "Change from baseline in CSDD(Cornell scale for depression in dementia) at week 4, 8, 16 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24weeks"
            }, 
            {
                "description": "Change from baseline in K-MMSE at week 12 and 24.", 
                "measure": "Change from baseline in K-MMSE at week 12 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change from baseline in ADAS-Cog at week 12 and 24.", 
                "measure": "Change from baseline in ADAS-Cog at week 12 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change from baseline in NPIQ at week 12 and 24.", 
                "measure": "Change from baseline in NPIQ at week 12 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change from baseline in S-IADL at week 12 and 24.", 
                "measure": "Change from baseline in S-IADL at week 12 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change from baseline in GDS-15 at week 4, 8, 12, 16 and 24.", 
                "measure": "Change from baseline in GDS-15 at week 4, 8, 12, 16 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change from baseline in CDR at week 12 and 24.", 
                "measure": "Change from baseline in CDR at week 12 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change from baseline in CDR sum of box at week 12 and 24.", 
                "measure": "Change from baseline in CDR sum of box at week 12 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change from baseline in Pittsburgh Sleep Quality Index at week 12 and 24.", 
                "measure": "Change from baseline in Pittsburgh Sleep Quality Index at week 12 and 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Konkuk University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Konkuk University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}